Skip to main content

Abstract

In the 1970s cancer therapy became the focus of the increasingly politically powerful, critical health movement in America, highlighting the failures and severe side-effects of conventional cancer treatments: surgery, radiation and chemotherapy. Faced with unprecedented public criticism of the low success rate of the costly ‘battle against cancer’, the American cancer establishment was seriously under attack. It needed a scientific promise that suited the growing public demand for effective and less toxic cancer remedies. The politically well-informed supporters of a new type of cancer agent, named ‘interferon’, capitalized on this need and the popular desire for more natural and organic remedies. In publicly emphasizing the presumed non-toxic and natural qualities of interferon as both an unorthodox organic and science-based promise in the fight against cancer, they succeeded in getting interferon absorbed in the accelerating politics and economics of the American cancer scene. With the press blossoming into the most important agenda-setting forum, a boom in expectations was fuelled world wide, resulting in interferon acquiring ‘miracle drug’ status in the late 1970s.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

  1. D. Cantor, ‘Cortisone and the Politics of Drama, 1949–1955’ in J. Pickstone (ed.), Medical Innovations in Historical Perpsective (London: Macmillan, 1992), pp. 165–84.

    Google Scholar 

  2. A. Yoshioka, ‘Streptomycin in Postwar Britain: a Cultural History of a Miracle Drug’, in M. Gijswijt-Hofstra, G. M. van Heteren and E. M. Tansey, Biographies of Remedies (Amsterdam: Rodopi, 2002), pp. 203–28.

    Google Scholar 

  3. R. Bud, ‘Penicillin and the new Elizabethans’, British Journal of the History of Science, 31 (1998), 305–33.

    Article  Google Scholar 

  4. For an extensive account of the early development of interferon, see T. Pieters, ‘Interferon and its First Clinical Trial: Looking Behind the Scenes’, Medical History, 37 (1993), 270–95.

    Article  Google Scholar 

  5. R. A. Rettig, Cancer Crusade (Princeton: Princeton University Press, 1977), p. 18.

    Google Scholar 

  6. S. Panem, The Interferon Crusade (Washington, D.C.: Brookings Institution, 1984), p. 16; and interview with M. Krim, 11 November 1992, New York.

    Google Scholar 

  7. J. T. Patterson, The Dread Disease: Cancer and Modern American Culture (Cambridge, MA: Harvard University Press, 1987), pp. 256–68.

    Google Scholar 

  8. M. Edelhart, Interferon: the New Hope for Cancer (Reading: Addison-Wesley, 1981), p. 146.

    Google Scholar 

  9. N. Wade, ‘Cloning Gold Rush Turns Basic Biology into Big Business’, Science, 208 (1980) 688–92;

    Article  Google Scholar 

  10. S. Andreopoulos, ‘Sounding Board: Gene Cloning by Press Conference’, New England Journal of Medicine, 302 (1980), 743–6.

    Article  Google Scholar 

  11. The use of the penicillin analogy was reiterative in the sense that journalists as well as interferon researchers made frequent use of it in their performances; K. Cantell, ‘Why is Interferon not in Clinical Use Today?’, in I. Gresser (ed.), Interferon (London: Academic Press, 1979), pp. 2–28, p. 3.

    Google Scholar 

  12. Editorial, ‘What Not to Say about Interferon’, Nature, 285 (1980), 603–4.

    Article  Google Scholar 

  13. T. Pieters, ‘Marketing Medicines through Randomised Controlled Trials: the Case of Interferon’, British Medical Journal, 317 (1998), 1231–3.

    Article  Google Scholar 

  14. Cantor, ‘Cortisone and the Politics of Drama’, p. 173; H. M. Marks, ‘Cortisone, 1949: a Year in the Political Life of a Drug’, Bulletin for the History of Medicine, 66 (1992), 419–39.

    Google Scholar 

  15. For a comprehensive account of medicine and the counter culture in Britain and America in the second half of the twentieth century, see M. Saks, ‘Medicine and the Counter Culture’, in R. Cooter and J. Pickstone (eds), Medicine in the 20th Century (Amsterdam: Harwood, 2000), pp. 113–23.

    Google Scholar 

  16. Bert Hansen argues convincingly that the high media visibility of therapeutic discoveries in America originates from as early as the 1880s: B. Hansen, ‘New Images of a New Medicine: Visual Evidence for the Widespread Popularity of Therapeutic Discoveries in America after 1885’, Bulletin of the History of Medicine, 73 (1999), 629–78.

    Article  Google Scholar 

  17. Karpf’s pioneering study examines the dynamics of mediating health and medicine by the mass media from the 1930s up to the 1980s: A. Karpf, Doctoring the Media (London: Routledge, 1988), pp. 9–31.

    Google Scholar 

  18. R. Porter, The Greatest Benefit to Mankind: a Medical History of Humanity from Antiquity to the Present (London: Harper Collins Publishers, 1997), p. 718.

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Copyright information

© 2004 Palgrave Macmillan, a division of Macmillan Publishers Limited

About this chapter

Cite this chapter

Pieters, T. (2004). Hailing a Miracle Drug: the Interferon. In: de Blécourt, W., Usborne, C. (eds) Cultural Approaches to the History of Medicine. Palgrave Macmillan, London. https://doi.org/10.1057/9780230287594_12

Download citation

  • DOI: https://doi.org/10.1057/9780230287594_12

  • Publisher Name: Palgrave Macmillan, London

  • Print ISBN: 978-1-349-51239-3

  • Online ISBN: 978-0-230-28759-4

  • eBook Packages: Palgrave History CollectionHistory (R0)

Publish with us

Policies and ethics